Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of Steven Gannon to its Board of Directors. Mr. Gannon will also serve as chair of Fusion’s Audit Committee.
“Mr. Gannon brings to Fusion deep corporate finance and operational expertise in the biopharmaceutical industry and his proven execution of business development and strategic transactions will be invaluable as we advance our Fast-Clear™ Linker technology platform to deliver novel therapies,” said Damian Lamb, chairman of the board of directors. “We are pleased to add his financial and operational acumen as an independent member of our board.”
Mr. Gannon was most recently chief financial officer, senior vice president of finance and treasurer at Aptalis Pharma Inc., until it was acquired by Forest Laboratories Inc. Prior to joining Aptalis, Mr. Gannon served as chief financial officer for Cryocath Technologies Inc., which was acquired by Medtronic Inc. Prior to Cryocath, Mr. Gannon served as head of finance and administration of the research division of AstraZeneca Canada Inc. and chief financial officer of Mallinckrodt Medical Inc.’s Canadian operations. Mr. Gannon currently serves on the boards of directors and as chairman of the audit committees of Aerogen, enGene Inc., and LABORIE Medical Technologies, and on the board of directors and as a member of the audit committee of Xenon Pharmaceuticals. Previously, he served on the board of directors of Advanced Accelerator Applications SA. He received a bachelor of commerce from Concordia University in Montreal and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario. Mr. Gannon is a Certified Public Accountant (CPA) and Chartered Accountant (CA).
“Fusion is differentiated within the oncology space with a proprietary platform technology to develop next-generation radiopharmaceuticals for precision oncology and established manufacturing and supply chain capabilities,” said Mr. Gannon. “The company is well positioned for growth and I look forward to helping guide the strategic direction.”
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. Using its proprietary Fast-Clear™ Linker Technology platform, the company attaches alpha particle emitting isotopes to targeting molecules to create novel, next-generation radiopharmaceuticals for the treatment of cancer. In preclinical studies, the company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue. Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial. The company completed an oversubscribed $125M Series B financing that will be used to advance FPI-1434 and initiate preclinical and clinical development on multiple new product candidates.
To further leverage its proprietary platform, Fusion is actively evaluating opportunities to in-license targeting molecules and form strategic partnerships to expand its pipeline of cancer therapies. For more information, please visit www.fusionpharma.com or contact email@example.com.